Mass spectrometric identification of proteotypic peptides from clinically used tumor markers

Yan Li, Lori J. Sokoll, Peter E. Barker, Hui Zhang, Daniel W. Chan

Research output: Contribution to journalArticlepeer-review


Introduction: With the rapid development of mass spectrometry-based technologies such as multiple reaction monitoring and heavy-isotope-labeled- peptide standards, quantitative analysis of biomarker proteins using mass spectrometry is rapidly progressing toward detection of target proteins/peptides from clinical samples. Proteotypic peptides are a few peptides that are repeatedly and consistently identified from a protein in a mixture and are used for quantitative analysis of the protein in a complex biological sample by mass spectrometry. Materials and Methods: Using mass spectrometry, we identified peptide sequences and provided a list of tryptic peptides and glycopeptides as proteotypic peptides from five clinically used tumor markers, including prostate-specific antigen, carcinoembryonic antigen, Her-2, human chorionic gonadotropin, and CA125. Conclusion: These proteotypic peptides have potential for targeted detection as well as heavy-isotope-peptide standards for quantitative analysis of marker proteins in clinical specimens using a highly specific, sensitive, and high-throughout mass spectrometry-based analysis method.

Original languageEnglish (US)
Pages (from-to)58-66
Number of pages9
JournalClinical Proteomics
Issue number1-2
StatePublished - Jun 2008


  • Cancer diagnostics
  • Glycopeptide
  • Mass spectrometry
  • Proteotypic peptide
  • Tumor marker

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'Mass spectrometric identification of proteotypic peptides from clinically used tumor markers'. Together they form a unique fingerprint.

Cite this